Recent Press Releases

Actavis Completes Acquisition of Auden Mckenzie

DUBLIN, June 1, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has completed its acquisition of Auden Mckenzie Holdings Limited, a dynamic and fast growing company focused on...


-- New data from Phase II NeoSphere study provide additional evidence on the role of Perjeta in the neoadjuvant (pre-surgery) treatment of HER2-positive early breast cancer -- Chicago – June...

Study Finds Initial Nivolumab-Based Treatment Halts Melanoma Progression

A randomized phase III trial indicates that initial therapy with nivolumab alone or in combination with ipilimumab is significantly more effective than ipilimumab alone. Nivolumab alone more than...

New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed Chronic Lymphocytic Leukemia

An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients with chronic-lymphocytic leukemia (CLL) that...

Novel Targeted Drug Palbociclib Slows Progression of Hormone Receptor-Positive Breast Cancer

The phase III registration study PALOMA-31 reports that adding the investigational targeted agent palbociclib to standard hormonal therapy (fulvestrant) more than doubled the duration of disease...

Obinutuzumab Doubles Remission Duration in Patients With Relapsed, Indolent Non-Hodgkin Lymphoma

Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent...

PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting

INDIANAPOLIS, May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced final results of

Lilly to Present CYRAMZA® (ramucirumab) Data at 2015 ASCO Annual Meeting

INDIANAPOLIS, May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that data from se

Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data

INDIANAPOLIS, May 28, 2015  /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Na

Amgen Launches Program To Further Advance Basic Biology Research

More Than 1,000 Tools and Resources Made Available to Academic Institutions Including Small Molecules, Peptides, Antibodies and Recombinant Proteins, Engineered Cell Lines, and Genetically-Enginee

Salix Announces FDA Approval of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea)

Xifaxan® 550 mg is the first-and-only nonsystemic antibiotic approved for the treatment of IBS-D in adults LAVAL, Quebec, May 27, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International,...

Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults

-First in class treatment for IBS-D treats hallmark symptoms of IBS-D; abdominal pain and diarrhea - IBS-D can be debilitating, affecting up to 15 million Americans, and there are limited...

Johnson & Johnson Announces Acceptance of Binding Offer From Cardinal Health To Acquire Cordis

NEW BRUNSWICK, N.J., May 28, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the acceptance of the March 1, 2015 binding offer from Cardinal Health to acquire its Cordis...

AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena(R)

Company Affirms 2015 Financial Outlook WALTHAM, Mass., May 28, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), today announced that it has received a complete response letter...

Starting antiretroviral treatment early improves outcomes for HIV-infected individuals

Starting antiretroviral treatment early improves outcomes for HIV-infected individuals NIH-funded trial results likely will impact global treatment guidelines For Immediate Release: Wednesday, May...

Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association's 75th Scientific Sessions®

Clinical and pre-clinical data on compounds representing several of the largest diabetes treatment classes will be presented


U.S. Food and Drug Administration Approves Humalog® 200 units/mL KwikPen®

Marks approval of first concentrated mealtime insulin analog in the U.S.

Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment

SAN DIEGO, May 27, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Amgen To Advance Understanding Of The Treatment Of Blood Cancers At 20th Congress of European Hematology Association (EHA)

THOUSAND OAKS, Calif., May 27, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present